GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals

Overton, Edgar Turner; Sungkanuparph, Somnuek; Klebert, Michael; Royal, Michael; Demarco-Shaw, Debra; Powderly, William G.; Aberg, Judith A.

doi:10.2174/1874357901105010109

Cited by 9 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But on day 210, the seroconversion rate did not differ (72 vs 60%, p D 0.23). Two RCT by Overton et al, 73,100 however, did not confirm these results. In the first one, their patients received 250mg GM-CSF as an adjuvant to a 40 mg accelerated schedule at 0-1-3 months but the vaccine-alone group had better response rates (65.2 vs 52.4%, NSD).…”

Section: Is There a Place For Adjuvants For Hbv Vaccination In Peoplementioning

confidence: 90%

“…Numerous studies, from retrospective studies to randomized control trials (RCT), have found a correlation between undetectable HIV RNA, a high CD4 cell count and higher vaccination success. 19,20,23,27,30,60,63,75,[93][94][95][96][97]100 The HIV viral load even seems to be more important than the CD4 count [19, 21, 23,], even though a positive correlation between the CD4 cell count at the time of (re)vaccination and the response to vaccination was observed in many studies. 10,11,20,22,23,95 Other predictors of a poor response include HCV co-infection, poor general health status and occult hepatitis B 7 often observed in people living with HIV.…”

Section: Reinforced Vaccination Strategies In People Living With Hiv mentioning

confidence: 99%

“…In the first one, their patients received 250mg GM-CSF as an adjuvant to a 40 mg accelerated schedule at 0-1-3 months but the vaccine-alone group had better response rates (65.2 vs 52.4%, NSD). 73 In the latest one, 100 comparing the adjunction of 250mg of GM-CSF to a classic schedule, the authors found that only 35% of persons receiving GM-CSF developed protective sAb while 50% in vaccine only arm developed protection (P D 0.47). Overall, only 28% of subjects maintained protective Ab 1 y after vaccination.…”

Section: Is There a Place For Adjuvants For Hbv Vaccination In Peoplementioning

confidence: 99%

See 2 more Smart Citations

Hepatitis B virus vaccination in HIV-infected people: A review

Catherine

Piroth

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

HBV immunization is highly recommended in people infected with HIV. However, the classical schedule used in the general population has been shown to be insufficient in people living with HIV. This review summarizes the main studies dealing with HBV vaccination in people living with HIV, depending on their baseline status (in particular, never vaccinated, already vaccinated, or with an isolated anti-HBc serological profile). It shows that reinforced 40µg intramuscular HBV vaccination schedules are now frequently recommended, either initially in people never vaccinated, or in the lack of an anamnestic response in other situations. Adjuvants cannot be currently recommended. Anti-HBs titers have to be checked 1 to 2 months following the last vaccine dose, and annually thereafter a booster is necessary if antiHBs titers decrease below 10 mIU/mL. In patients with a CD4 cell count <200/µL, guidelines recommend starting the vaccination regimen as soon as possible after HAART has been started.

show abstract

Section: Is There a Place For Adjuvants For Hbv Vaccination In Peoplementioning

confidence: 90%

Section: Reinforced Vaccination Strategies In People Living With Hiv mentioning

confidence: 99%

Section: Is There a Place For Adjuvants For Hbv Vaccination In Peoplementioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B virus vaccination in HIV-infected people: A review

Catherine

Piroth

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…It was reported that when the HBV-S gene is fused to the GM-CSF gene, the immune responses induced by HBV-DNA plasmids both in normal and HBV-transgenic mice can be strengthened, and HBV-DNA plasmids fused with GM-CSF may be used for prevention and treatment [142], but meanwhile, it also showed that GM-CSF was not able to improve the antibody (Ab) titer or the development of protective immunity by the HBV vaccination in healthy adult nonresponders [142]. Recently, another study revealed that GM-CSF failed to improve responses to the booster HBV vaccination in HIV-infected individuals [143]. Thus, whether GM-CSF is an optimal vaccination strategy needs to be evaluated.…”

Section: Experimentally Therapeutic Applications Of Cytokines and Thementioning

confidence: 99%

Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections

Liu

Tian

et al. 2014

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a worldwide health problem, with approximately one third of populations have been infected, among which 3-5% of adults and more than 90% of children developed to chronic HBV infection. Host immune factors play essential roles in the outcome of HBV infection. Thus, ineffective immune response against HBV may result in persistent virus replications and liver necroinflammations, then lead to chronic HBV infection, liver cirrhosis, and even hepatocellular carcinoma. Cytokine balance was shown to be an important immune characteristic in the development and progression of hepatitis B, as well as in an effective antiviral immunity. Large numbers of cytokines are not only involved in the initiation and regulation of immune responses but also contributing directly or indirectly to the inhibition of virus replication. Besides, cytokines initiate downstream signaling pathway activities by binding to specific receptors expressed on the target cells and play important roles in the responses against viral infections and, therefore, might affect susceptibility to HBV and/or the natural course of the infection. Since cytokines are the primary causes of inflammation and mediates liver injury after HBV infection, we have discussed recent advances on the roles of various cytokines [including T helper type 1 cells (Th1), Th2, Th17, regulatory T cells (Treg)-related cytokines] in different phases of HBV infection and cytokine-related mechanisms for impaired viral control and liver damage during HBV infection. We then focus on experimental therapeutic applications of cytokines to gain a better understanding of this newly emerging aspect of disease pathogenesis.

show abstract

“…We excluded 43 studies some of which were non-randomised (Abzug 2009; Alaei 2003; Bailey 2008; Carne 1987; Horster 2010; Kalinowska-Nowak 2007; Koblin 1999; Lao-Araya 2011; Loke 1990; Paitoonpong 2008; Sellar 2009; Thaithumyanon 2002; Wilson 2001; Wursthorn 2011), not in PLHIV (Altuntas 2011; Mehta 2010; Mehta 2010a; Miller 1989; Odaka 1988; Pasricha 2005; Thompson 1998) testing adjuvants to hepatitis B vaccine (Cooper 2005a; Cooper 2008; Overton 2010; Overton 2011; Sasaki 2003; Sayad 2012); testing modalities of administering hepatitis B vaccine (Bunupuradah 2011; de Vries-Sluijs 2011; Flynn 2011; Fonseca 2005; Hwang 2010; Launay 2011; McQuillan 2010) vaccines targeting other conditions (Johnson 1999; Kintu 2013; Launay 2011a). See Characteristics of excluded studies.…”

Section: Resultsmentioning

confidence: 99%